CEO of Immune-Onc Therapeutics, Inc., a clinical-stage biotech company developing a novel class of myeloid checkpoint inhibitors for cancer immunotherapy. www.Immune-Onc.com 2002-2016, Genentech, led development efforts across the product lifecycle in a variety of therapeutic areas including: oncology, immunology, infectious diseases, metabolic disorders, and neurosciences. Began biotech career as a scientist at Tularik, before its acquisition by Amgen. Ph.D. from Brandeis University in the laboratory of Dr. Michael Rosbash, winner of 2017 Nobel Prize in Physiology or Medicine. Postdoc research in immunology at UCSF, as Fellow of the Damon Runyon Cancer Research Fund in the laboratory of Dr. Dan Littman and a Special Fellow of the Leukemia and Lymphoma Society (LLS) in the laboratory of Dr. Art Weiss.